NCT01217450View on ClinicalTrials.gov

Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

May 31, 2014

Conditions

Recurrent Colon CancerRecurrent Rectal CancerStage IVA Colon CancerStage IVA Rectal CancerStage IVB Colon CancerStage IVB Rectal CancerUnspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

selumetinib

Given orally

BIOLOGICAL

cetuximab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (3)

20892

National Cancer Institute Medicine Branch, Bethesda

53226

Wisconsin Clinical Cancer Center, Milwaukee

53792

University of Wisconsin Hospital and Clinics, Madison

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT01217450 - Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter